Increased Intestinal Absorption in the Era of Teduglutide and Its Impact on Management Strategies in Patients With Short Bowel Syndrome–Associated Intestinal Failure. Issue 2 (23rd January 2013)

• Record Type: Journal Article
• Authors: Seidner, Douglas L.; Schwartz, Lauren K.; Winkler, Marion F.; Jeejeebhoy, Khursheed; Boullata, Joseph I.; Tappenden, Kelly A.
• Is Part Of: JPEN, Journal of parenteral and enteral nutrition. Volume 37:Issue 2(2013)
• Page Start: 201
• Page End: 211
• Publication Date: 2013-01-23
• Subjects: intestinal failure -- short bowel syndrome -- malabsorption -- multidisciplinary care -- teduglutide -- GLP‐2 -- fluid balance -- parenteral nutrition -- treatment; Parenteral feeding -- Periodicals; Enteral feeding -- Periodicals; 615.85484
• DOI: 10.1177/0148607112472906
• Languages: English
• ISSNs: 0148-6071

Abstract

Abstract : Short bowel syndrome–associated intestinal failure (SBS‐IF) as a consequence of extensive surgical resection of the gastrointestinal (GI) tract results in a chronic reduction in intestinal absorption. The ensuing malabsorption of a conventional diet with associated diarrhea and weight loss results in a dependency on parenteral nutrition and/or intravenous fluids (PN/IV). A natural compensatory process of intestinal adaptation occurs in the years after bowel resection as the body responds to a lack of sufficient functional nutrient‐processing intestinal surface area. The adaptive process improves bowel function but is a highly variable process, yielding different levels of symptom control and PN/IV independence among patients. Intestinal rehabilitation is the strategy of maximizing the absorptive capacity of the remnant GI tract. The approaches for achieving this goal have been limited to dietary intervention, antidiarrheal and antisecretory medications, and surgical bowel reconstruction. A targeted pharmacotherapy has now been developed that improves intestinal absorption. Teduglutide is a human recombinant analogue of glucagon‐like peptide 2 that promotes the expansion of the intestinal surface area and increases the intestinal absorptive capacity. Enhanced absorption has been shown in clinical trials by a reduction in PN/IV requirements in patients with SBS‐IF. This article details the clinical considerations and best‐practice recommendations for intestinal rehabilitation, including optimization of fluids, electrolytes, and nutrients; the integration of teduglutide therapy; and approaches to PN/IV weaning.